Missouri Challenges Eli Lilly Over 340B Data Requirements
Hospitals should review manufacturer data mandates as state officials challenge the terms required to access federal drug discounts.
Updated on Oct. 26, 2026 in Healthcare
Live Poll
Should drug manufacturers be allowed to require patient data for hospitals to receive price discounts?
The Missouri Attorney General issued a cease-and-desist letter to drug manufacturer Eli Lilly, alleging the company used improper market power to restrict access to federal 340B drug discounts. This regulatory action follows a dispute over claims data that led Eli Lilly to end pricing access for University of Missouri Health Care in July.
Why it matters
The dispute centers on mandatory claims-data sharing, a requirement Eli Lilly uses to verify 340B eligibility but which state officials argue serves to unfairly inflate drug costs for providers. For operators, this conflict signals a growing compliance and data-privacy friction point between pharmaceutical manufacturers and health systems.
Eli Lilly discontinued 340B pricing for University of Missouri Health Care in July, cutting off discounts until the system agreed to provide sensitive claims data. The program remains the primary federal mechanism intended to lower medication costs for safety-net providers.
The players
Eli Lilly
A global pharmaceutical manufacturer that develops and markets medicines for chronic health conditions.
University of Missouri Health Care
A regional academic health system that serves patients and participates in federal pharmaceutical discount programs.
Catherine Hanaway
The Attorney General of Missouri responsible for state-level legal enforcement and consumer protection.
The details
Eli Lilly requires hospitals to share sensitive patient claims data to maintain participation in the 340B discount program. When University of Missouri Health Care refused to comply with this data reporting demand, the company terminated their pricing access. The hospital network has since agreed to share data temporarily to restore the discounts while the Attorney General challenges the manufacturer's authority to impose these conditions.
Timeline
July 2026: Eli Lilly stopped 340B pricing for MU Health Care.
October 26, 2026: The Missouri Attorney General announced the cease-and-desist letter.
Market Landscape
This enforcement action marks an escalation in state-level efforts to challenge how pharmaceutical firms administer the federal 340B Drug Pricing Program. It reflects a wider trend of regulatory pushback against manufacturers that unilaterally impose new data-reporting requirements on health systems.
Operators in the healthcare space should monitor whether these reporting requirements set a broader standard for vendor contracts or invite further state-level litigation. Ensure that legal counsel reviews any manufacturer-imposed data-sharing mandates for alignment with existing 340B program guidance.
The takeaway
This case highlights the operational risk of navigating manufacturer data mandates that conflict with institutional privacy policies. Affected providers should ensure their compliance teams have documented protocols for 340B data submissions and monitor the Attorney General's office website for further guidance.
Further reading
For broader context on how pharmacy policy impacts local clinical operations, explore Healthcare.
Live Poll
Should drug manufacturers be allowed to require patient data for hospitals to receive price discounts?
